

Letter to the Editor

Effects of Thalidomide on Endothelial Activation and Stress Index in Children with β -Thalassemia Major

Keywords: Thalidomide; Endothelial Activation; Stress Index; Children; β -thalassemia major.

Published: November 01, 2024

Received: August 20, 2024

Accepted: October 07, 2024

Citation: Chen J., Kong W., Xiao J., Liu X., Yang K. Effects of Thalidomide on Endothelial Activation and stress index in children with β -thalassemia major. *Mediterr J Hematol Infect Dis* 2024, 16(1): e2024076, DOI: <http://dx.doi.org/10.4084/MJHID.2024.076>

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by-nc/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

To the editor.

β -thalassemia major (TM) is a congenital hemolytic disease characterized by reduced or absent β -globin production, hemolysis from resulting unstable β -globin tetramers, ineffective erythropoiesis, and severe anemia that is fatal in the absence of life-long red cell transfusions.¹ Hematopoietic stem cell transplantation (HSCT) remains the only curative option, achieving thalassemia-free survival rates as high as 97%.² However, HSCT presents various risks, particularly in older children and those without a fully matched donor, limiting its widespread use. The Endothelial Activation and Stress Index (EASIX) is a biomarker calculated using lactate dehydrogenase (LDH), creatinine, and platelet counts and is significantly associated with complications and mortality after transplantation.³⁻⁶ Thalidomide, known for inducing fetal hemoglobin production, can effectively increase hemoglobin levels in TM patients, often serving as a bridging treatment. However, the impact of pre-transplant thalidomide treatment on transplant outcomes remains uncertain. This study evaluates the changes in EASIX following thalidomide treatment in children with TM.

We retrospectively assessed children with TM who received thalidomide for more than three months between May 2021 and June 2024. The study included 25 patients (15 males and 10 females) aged 14-18 years. The EASIX score was calculated using $\text{LDH (U/L)} \times \text{creatinine (mg/dL)} / \text{platelet count} (\times 10^9/\text{L})$ from laboratory data recorded after approximately three months of thalidomide treatment. A significant reduction in EASIX was observed in TM patients post-treatment ($p=0.002$) (**Figure 1**). We investigated the correlations between EASIX and baseline indicators. In addition to platelets ($r=-0.601$, $p=0.001$), LDH ($r=0.536$, $p=0.006$), and creatinine ($r=0.595$, $p=0.002$), EASIX was inversely correlated with white blood cell count ($r=-0.450$, $p=0.024$) and positively correlated with total bilirubin ($r=0.615$, $p=0.001$) and indirect bilirubin ($r=0.561$, $p=0.004$). No other significant correlations




Figure 1. 25 children with β -thalassemia major were detected Endothelial Activation and Stress Index (EASIX) before and after thalidomide treatment (TT).

were found between EASIX and other parameters.

Patients with thalassemia undergoing transplantation suffer a unique spectrum of complications, particularly those related to vascular endothelial injury, such as hepatic venular occlusive disease/sinusoidal obstruction syndrome (VOD/SOS), transplant-associated thrombotic microangiopathy, and graft-versus-host disease.⁷ VOD/SOS incidence in thalassemia transplants can reach 10.4%.⁸ Increased markers of endothelial cell damage in thalassemia patients are closely linked to post-transplantation thrombotic microangiopathy.^{9,10} Therefore, understanding and addressing endothelial injury in these patients is crucial for improving transplant outcomes.

Although endothelial dysfunction is associated with various transplant complications, clear biomarkers are limited. EASIX, first reported in 2017 by Luft et al.,³ is strongly correlated with transplant outcomes. In patients with SOS/VOD, EASIX was significantly higher on the day of transplantation than in those without SOS/VOD.⁴ Elevated EASIX at different time points during

transplantation is associated with higher mortality and poorer overall survival.⁵ In TM patients, median EASIX is significantly higher in those with day +100 transplant-related mortality.⁶ Consequently, EASIX can serve as a valuable indicator of vascular endothelial injury during transplantation, guiding early interventions to reduce complications and improve prognosis.

Thalidomide has emerged as a treatment option for β -thalassemia, with demonstrated benefits in reactivating fetal hemoglobin production and reducing transfusion needs.¹¹ Additionally, it has been shown to ameliorate erythropoiesis and iron homeostasis, reduce spleen size, and treat thrombocytopenia in hypersplenism.^{12,13} In this study, we evaluated the effects of thalidomide on EASIX and analyzed the correlations between baseline indicators and EASIX to explore the support of the effectiveness of this drug. After thalidomide treatment, a significant reduction in EASIX was found in patients with TM, which may affect transplant outcomes and provide supporting

evidence for pre-transplant use. In these 25 TM patients, treatment with thalidomide resulted in a significant reduction in LDH levels (291.0 ± 97.7 vs. 236.4 ± 51.7 U/L, $p=0.003$). In contrast, no significant changes were observed in creatinine (0.50 ± 0.15 vs. 0.48 ± 0.16 mg/dL, $p=0.451$) or platelet count (257 ± 150 vs. $271 \pm 138 \times 10^9/L$, $p=0.376$). Thus, we believe that the improvement in EASIX is attributable to the alleviation of anemia and hemolysis, reducing iron overload, which is the main risk factor for thalassemia transplants.¹⁴

In summary, this study is the first to assess thalidomide's impact on EASIX in children with TM, offering new insights into its potential role as a pretransplantation therapy. Thalidomide treatment is a potential way to bridge patients to transplantation.

Ethics Statement. The study protocol was approved by the Medical Ethics Committee of the First People's Hospital of Zigong.

Jie Chen^{1, #}, Wenqiang Kong^{2, #}, Jian Xiao¹, Xiaodong Liu¹ and Kun Yang^{1,3}.

¹ Department of Hematology, Zigong First People's Hospital, Zigong, China.

² Department of Pharmacy, Zigong First People's Hospital, Zigong, China.

³ Department of Hematology, West China Hospital, Sichuan University, Chengdu, China.

[#] Both authors contributed equally to this work.

Competing interests: The authors declare no conflict of Interest.

Correspondence to: Kun Yang. Department of Hematology, Zigong First People's Hospital, Zigong, China; West China Hospital, Sichuan University, Chengdu, China. E-mail: 1759874951@qq.com

References:

1. Kattamis A, Kwiatkowski JL, Aydinok Y. Thalassaemia. *Lancet*. 2022;399:2310-24. [https://doi.org/10.1016/S0140-6736\(22\)00536-0](https://doi.org/10.1016/S0140-6736(22)00536-0)
2. Liang H, Pan L, Xie Y, Fan J, Zhai L, Liang S, Zhang Z, Lai Y. Health-related quality of life in pediatric patients with beta-thalassemia major after hematopoietic stem cell transplantation. *Bone Marrow Transplant*. 2022;57:1108-15. <https://doi.org/10.1038/s41409-022-01663-0>
3. Luft T, Benner A, Jodele S, Dandoy CE, Storb R, Gooley T, Sandmaier BM, Becker N, Radujkovic A, Dreger P, Penack O. EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis. *Lancet Haematol*. 2017;4:e414-e23. [https://doi.org/10.1016/S2352-3026\(17\)30108-4](https://doi.org/10.1016/S2352-3026(17)30108-4)
4. Jiang S, Penack O, Terzer T, Schult D, Majer-Lauterbach J, Radujkovic A, Blau IW, Bullinger L, Muller-Tidow C, Dreger P, Luft T. Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel. *Haematologica*. 2021;106:446-53. <https://doi.org/10.3324/haematol.2019.238790>
5. Mariotti J, Magri F, Giordano L, De Philippis C, Sarina B, Mannina D, Taurino D, Santoro A, Bramanti S. EASIX predicts non-relapse mortality after haploidentical transplantation with post-transplant cyclophosphamide. *Bone Marrow Transplant*. 2023;58:247-56. <https://doi.org/10.1038/s41409-022-01874-5>
6. Kulkarni UP, Pai AA, Kavitha ML, Selvarajan S, Lionel S, Devasia AJ, Korula A, Fouzia NA, Sindhuvi E, Abraham A, Srivastava A, Mathews V, George B, Balasubramanian P. Endothelial Activation and Stress Index-Measured Pretransplantation Predicts Transplantation-Related Mortality in Patients with Thalassemia Major Undergoing Transplantation with Thiopeta, Treosulfan, and Fludarabine Conditioning. *Transplant Cell Ther*. 2022;28:356 e1- e6. <https://doi.org/10.1016/j.jtct.2022.05.001>
7. Milone G, Bellofiore C, Leotta S, Milone GA, Cupri A, Duminuco A, Garibaldi B, Palumbo G. Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology. *J Clin Med*. 2022;11. <https://doi.org/10.3390/jcm11030623>
8. Lai X, Liu L, Zhang Z, Shi L, Yang G, Wu M, Huang R, Liu R, Lai Y, Li Q. Hepatic veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic stem cell transplantation for thalassemia major: incidence, management, and outcome. *Bone Marrow Transplant*. 2021;56:1635-41. <https://doi.org/10.1038/s41409-021-01233-w>
9. Caprari P, Profumo E, Massimi S, Buttari B, Rigano R, Regine V, Gabbianelli M, Rossi S, Risoluti R, Materazzi S, Gullifa G, Maffei L, Sorrentino F. Hemorheological profiles and chronic inflammation markers in transfusion-dependent and non-transfusion-dependent thalassemia. *Front Mol Biosci*. 2022;9:1108896. <https://doi.org/10.3389/fmolb.2022.1108896>
10. Abusin GA, Abu-Arja R, Bajwa RPS, Horwitz EM, Auletta JJ, Rangarajan HG. Severe transplant-associated thrombotic microangiopathy in patients with hemoglobinopathies. *Pediatr Blood Cancer*. 2017;64. <https://doi.org/10.1002/pbc.26503>
11. Jian X, Liu X, Peng W, Li L, Hua F, Chen K, Zhang J, Luo S, Yang K, Wu Y. Long-term efficacy and safety of thalidomide treatment in children with beta-thalassemia major. *Pediatr Blood Cancer*. 2023:e30391. <https://doi.org/10.1002/pbc.30391>
12. Yang K, Liu X, Peng W, Hua F, Li L, Chen K, Zhang J, Luo S, Li W, Ding Y, Chen J, Xiao J. Effects of Thalidomide on Erythropoiesis and Iron Homeostasis in Transfusion-Dependent beta-Thalassemia. *Mediterr J Hematol Infect Dis*. 2024;16:e2024001. <https://doi.org/10.4084/MJHID.2024.001>

13. Chen Y, Cai N, Lai Y, Xu W, Li J, Huang L, Huang Y, Hu M, Yang H, Chen J. Thalidomide for the Treatment of Thrombocytopenia and Hypersplenism in Patients With Cirrhosis or Thalassemia. *Front Pharmacol.* 2020;11:1137.
<https://doi.org/10.3389/fphar.2020.01137>
14. Xu F., Tang C., Huang Y., Liang L., Huang F., Yang G., Peng P. Quantitative analysis of liver iron deposition based on dual-energy CT in thalassemia patients. *Mediterr J Hematol Infect Dis* 2023, 15(1): e2023020,
<https://doi.org/10.4084/MJHID.2023.020>